Abstract
BackgroundMethotrexate pneumonitis (MTX-P) is most frequently seen within the first year of treatment1 and is best avoided in established cases of Interstitial Lung disease (ILD). BSR recommends that if pre-treatment...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
